Biofrontera AG (FRA:B8FK)

Germany flag Germany · Delayed Price · Currency is EUR
2.690
0.00 (0.00%)
At close: Oct 15, 2025
Market Cap16.23M
Revenue (ttm)23.72M
Net Income (ttm)-964.00K
Shares Outn/a
EPS (ttm)-0.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume869
Average Volume92
Open2.600
Previous Close2.690
Day's Range2.600 - 2.780
52-Week Range2.010 - 3.000
Betan/a
RSI48.97
Earnings DateSep 30, 2025

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 88
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol B8FK
Full Company Profile

Financial Performance

In 2024, Biofrontera AG's revenue was 21.67 million, a decrease of -32.81% compared to the previous year's 32.25 million. Losses were -4.35 million, 1078.9% more than in 2023.

Financial Statements

News

There is no news available yet.